Literature DB >> 28742472

Bacteriophage endolysins and their applications.

Jude Ajuebor, Olivia McAuliffe, Jim O'Mahony, R Paul Ross, Colin Hill, Aidan Coffey.   

Abstract

Endolysins (lysins) are bacteriophage-encoded enzymes that have evolved to degrade specific bonds within the bacterial cell wall. These enzymes represent a novel class of antibacterial agents against infectious pathogens, especially in light of multidrug-resistant bacteria, which have made antibiotic therapy increasingly redundant. Lysins have been used successfully to eliminate/control bacterial pathogens in various anatomical locations in mouse and other animal models. Engineering tactics have also been successfully applied to improve lysin function. This review discusses the structure and function of lysins. It highlights protein-engineering tactics utilised to improve lysin activity. It also reviews the applications of lysins towards food biopreservation, therapeutics, biofilm elimination and diagnostics.

Entities:  

Year:  2016        PMID: 28742472     DOI: 10.3184/003685016X14627913637705

Source DB:  PubMed          Journal:  Sci Prog        ISSN: 0036-8504            Impact factor:   2.774


  8 in total

Review 1.  Recombinant Endolysins as Potential Therapeutics against Antibiotic-Resistant Staphylococcus aureus: Current Status of Research and Novel Delivery Strategies.

Authors:  Hamed Haddad Kashani; Mathias Schmelcher; Hamed Sabzalipoor; Elahe Seyed Hosseini; Rezvan Moniri
Journal:  Clin Microbiol Rev       Date:  2017-11-29       Impact factor: 26.132

2.  Characterization of a broad-spectrum endolysin LysSP1 encoded by a Salmonella bacteriophage.

Authors:  Yanhua Jiang; Dongqin Xu; Lianzhu Wang; Meng Qu; Fengling Li; Zhijun Tan; Lin Yao
Journal:  Appl Microbiol Biotechnol       Date:  2021-07-09       Impact factor: 4.813

Review 3.  Microbial-derived products as potential new antimicrobials.

Authors:  Bruce S Seal; Djamel Drider; Brian B Oakley; Harald Brüssow; David Bikard; Joseph O Rich; Stefan Miller; Estelle Devillard; Jason Kwan; Gérard Bertin; Stuart Reeves; Steven M Swift; Margot Raicek; Cyril G Gay
Journal:  Vet Res       Date:  2018-07-31       Impact factor: 3.683

4.  Recent advances in the treatment of C. difficile using biotherapeutic agents.

Authors:  Vo Van Giau; Hyon Lee; Seong Soo A An; John Hulme
Journal:  Infect Drug Resist       Date:  2019-06-10       Impact factor: 4.003

5.  Inhibition of L. monocytogenes Biofilm Formation by the Amidase Domain of the Phage vB_LmoS_293 Endolysin.

Authors:  Vincenzo Pennone; Marta Sanz-Gaitero; Paula O'Connor; Aidan Coffey; Kieran Jordan; Mark J van Raaij; Olivia McAuliffe
Journal:  Viruses       Date:  2019-08-06       Impact factor: 5.048

6.  Predicting Cell Wall Lytic Enzymes Using Combined Features.

Authors:  Xiao-Yang Jing; Feng-Min Li
Journal:  Front Bioeng Biotechnol       Date:  2021-01-06

Review 7.  The Advantages and Challenges of Using Endolysins in a Clinical Setting.

Authors:  Ellen Murray; Lorraine A Draper; R Paul Ross; Colin Hill
Journal:  Viruses       Date:  2021-04-15       Impact factor: 5.048

Review 8.  Endolysins against Streptococci as an antibiotic alternative.

Authors:  Kuan Yee Wong; Megat Hamzah Megat Mazhar Khair; Adelene Ai-Lian Song; Mas Jaffri Masarudin; Chou Min Chong; Lionel Lian Aun In; Michelle Yee Mun Teo
Journal:  Front Microbiol       Date:  2022-08-02       Impact factor: 6.064

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.